
Pharmacists have an opening to close chronic kidney disease (CKD) medication gaps as generic ACE inhibitors, ARBs, and SGLT2 inhibitors go underused.

Pharmacists have an opening to close chronic kidney disease (CKD) medication gaps as generic ACE inhibitors, ARBs, and SGLT2 inhibitors go underused.

A Peterson Health Technology Institute evaluation found virtual chronic kidney disease (CKD) care companies aren’t slowing kidney function decline or boosting medication adherence, despite billions invested.